What to expect when you take Mephyton and Metronidazole?

Do you take Mephyton and Metronidazole? Find out below what new side effects and undetected conditions people who are 50-59 years old may have. This prediction is created after we perform predictive analysis on health care big data. It will be updated regularly.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials).



On Oct, 21, 2018

6,180 reports have been studied.


Females aged 50 to 59 :

3,726 related reports were analyzed:

Most common symptoms:

Abdominal pain
  • 7.13% for females aged 50 (±5) who take Metronidazole
Acute kidney failure
  • 5.93% for females aged 50 (±5) who take Mephyton
Anaemia
  • 6.38% for females aged 50 (±5) who take Metronidazole
Ascites
  • 7.41% for females aged 50 (±5) who take Mephyton
Bleeding into the skin
  • 5.19% for females aged 50 (±5) who take Mephyton
Depression
  • 5.01% for females aged 50 (±5) who take Metronidazole
Diarrhea
  • 10.11% for females aged 50 (±5) who take Metronidazole
  • 6.67% for females aged 50 (±5) who take Mephyton
Dizziness
  • 6.54% for females aged 50 (±5) who take Metronidazole
Drug hypersensitivity
  • 5.24% for females aged 50 (±5) who take Metronidazole
Dyspnea
  • 6.04% for females aged 50 (±5) who take Metronidazole
Erythema multiforme
  • 8.89% for females aged 50 (±5) who take Mephyton
Fatigue
  • 6.67% for females aged 50 (±5) who take Mephyton
  • 6.54% for females aged 50 (±5) who take Metronidazole
Fever
  • 11.11% for females aged 50 (±5) who take Mephyton
  • 9.5% for females aged 50 (±5) who take Metronidazole
Haemoglobin decreased
  • 5.19% for females aged 50 (±5) who take Mephyton
Headache
  • 6.6% for females aged 50 (±5) who take Metronidazole
Hepatic failure
  • 10.37% for females aged 50 (±5) who take Mephyton
Hepatic trauma
  • 5.19% for females aged 50 (±5) who take Mephyton
Hepatitis
  • 5.19% for females aged 50 (±5) who take Mephyton
Hypoaesthesia
  • 5.15% for females aged 50 (±5) who take Metronidazole
Hypotension
  • 6.67% for females aged 50 (±5) who take Mephyton
Injury
  • 5.49% for females aged 50 (±5) who take Metronidazole
Joint pain
  • 5.37% for females aged 50 (±5) who take Metronidazole
Lactic acidosis
  • 5.19% for females aged 50 (±5) who take Mephyton
Metabolic acidosis
  • 5.19% for females aged 50 (±5) who take Mephyton
Multi-organ failure
  • 7.41% for females aged 50 (±5) who take Mephyton
Nausea
  • 11.06% for females aged 50 (±5) who take Metronidazole
  • 8.89% for females aged 50 (±5) who take Mephyton
Nausea and vomiting
  • 8.24% for females aged 50 (±5) who take Metronidazole
  • 5.19% for females aged 50 (±5) who take Mephyton
Oedema peripheral
  • 5.43% for females aged 50 (±5) who take Metronidazole
Osteonecrosis of jaw
  • 5.82% for females aged 50 (±5) who take Metronidazole
Pain
  • 10.75% for females aged 50 (±5) who take Metronidazole
Pancytopenia
  • 7.41% for females aged 50 (±5) who take Mephyton
Pleural effusion
  • 6.67% for females aged 50 (±5) who take Mephyton
Rash erythematous
  • 5.19% for females aged 50 (±5) who take Mephyton
Rashes
  • 6.91% for females aged 50 (±5) who take Metronidazole
Renal failure acute
  • 5.93% for females aged 50 (±5) who take Mephyton
Respiratory acidosis
  • 11.11% for females aged 50 (±5) who take Mephyton
Stress and anxiety
  • 9.16% for females aged 50 (±5) who take Metronidazole
Thrombocytopenia
  • 8.89% for females aged 50 (±5) who take Mephyton
Weakness
  • 7.69% for females aged 50 (±5) who take Metronidazole

Most common co-existing conditions:

Depression
  • 5.93% for females aged 50 (±5) who take Mephyton
  • 5.57% for females aged 50 (±5) who take Metronidazole
High blood pressure
  • 9.63% for females aged 50 (±5) who take Mephyton
  • 6.21% for females aged 50 (±5) who take Metronidazole
Nausea
  • 6.67% for females aged 50 (±5) who take Mephyton
Pain
  • 11.11% for females aged 50 (±5) who take Mephyton
  • 5.82% for females aged 50 (±5) who take Metronidazole
back to top

Males aged 50 to 59 :

2,454 related reports were analyzed:

Most common symptoms:

Acute kidney failure
  • 10.45% for males aged 50 (±5) who take Mephyton
Agranulocytosis
  • 7.27% for males aged 50 (±5) who take Mephyton
Anaemia
  • 7.27% for males aged 50 (±5) who take Mephyton
Arrhythmias
  • 5.45% for males aged 50 (±5) who take Mephyton
Blood creatinine increased
  • 5.45% for males aged 50 (±5) who take Mephyton
Chest pain
  • 10.91% for males aged 50 (±5) who take Mephyton
Chills
  • 5.0% for males aged 50 (±5) who take Mephyton
Cholestasis
  • 5.45% for males aged 50 (±5) who take Mephyton
Dehydration
  • 10.0% for males aged 50 (±5) who take Mephyton
Depression
  • 5.91% for males aged 50 (±5) who take Mephyton
Diarrhea
  • 6.62% for males aged 50 (±5) who take Metronidazole
  • 5.45% for males aged 50 (±5) who take Mephyton
Drug ineffective
  • 5.45% for males aged 50 (±5) who take Mephyton
Dyspnea
  • 10.45% for males aged 50 (±5) who take Mephyton
Erythema multiforme
  • 7.73% for males aged 50 (±5) who take Mephyton
Fatigue
  • 5.91% for males aged 50 (±5) who take Mephyton
  • 5.64% for males aged 50 (±5) who take Metronidazole
Fever
  • 10.45% for males aged 50 (±5) who take Mephyton
  • 8.28% for males aged 50 (±5) who take Metronidazole
Hepatic failure
  • 5.45% for males aged 50 (±5) who take Mephyton
Hypotension
  • 9.09% for males aged 50 (±5) who take Mephyton
  • 5.1% for males aged 50 (±5) who take Metronidazole
International normalised ratio increased
  • 9.55% for males aged 50 (±5) who take Mephyton
Multi-organ failure
  • 7.27% for males aged 50 (±5) who take Mephyton
Nausea
  • 7.73% for males aged 50 (±5) who take Mephyton
Nausea and vomiting
  • 5.91% for males aged 50 (±5) who take Mephyton
Oedema peripheral
  • 8.18% for males aged 50 (±5) who take Mephyton
Pleural effusion
  • 5.91% for males aged 50 (±5) who take Mephyton
Pneumonia
  • 6.36% for males aged 50 (±5) who take Mephyton
Rashes
  • 5.42% for males aged 50 (±5) who take Metronidazole
Renal failure acute
  • 11.82% for males aged 50 (±5) who take Mephyton
Sepsis
  • 6.82% for males aged 50 (±5) who take Mephyton
Septic shock
  • 6.36% for males aged 50 (±5) who take Mephyton
Stress and anxiety
  • 5.91% for males aged 50 (±5) who take Mephyton
Thrombocytopenia
  • 10.45% for males aged 50 (±5) who take Mephyton
Weight decreased
  • 5.91% for males aged 50 (±5) who take Mephyton

Most common co-existing conditions:

Crohn's disease
  • 5.95% for males aged 50 (±5) who take Metronidazole
Multiple myeloma
  • 9.09% for males aged 50 (±5) who take Mephyton
Pain
  • 6.36% for males aged 50 (±5) who take Mephyton
  • 5.15% for males aged 50 (±5) who take Metronidazole
back to top

Do you take Mephyton and Metronidazole:

  • To personalize this prediction to you, including to your gender, age, personal and family history, and more: Click here

Related studies

Mephyton

Mephyton has active ingredients of phytonadione. (latest outcomes from Mephyton 616 users)

Metronidazole

Metronidazole has active ingredients of metronidazole. It is often used in vaginitis bacterial. (latest outcomes from Metronidazole 28,507 users)

General study

Related publications that referenced our studies


Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on ePatient.care is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.